Bivariate or composite plots of endpoints.
Clinical trials often identify two endpoints or response measures of interest. Depending on the drugs and the disease, the endpoints may be correlated or uncorrelated, reflect efficacy or safety, or one or both may be considered as primary. For visualization, plots of each endpoint from baseline to the end of the trial are presented for each treatment group. This paper illustrates the usefulness of developing bivariate, composite plots of both endpoints jointly. Two applications are presented: one of a fixed combination drug for treating allergic rhinitis, and the other of a dose comparison trial in duodenal ulcer.
Peace
Karl E
KE
Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia, USA. kepeace@georgiasouthern.edu
Tsai
Kao-Tai
KT
D000403:Airway Resistance / Q000187:drug effects; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004381:Duodenal Ulcer / Q000188:drug therapy; D023381:Endpoint Determination; D006801:Humans; D014663:Nasal Decongestants / Q000627:therapeutic use; D054199:Pseudoephedrine / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy; D014311:Triprolidine / Q000627:therapeutic use
D018926:Anti-Allergic Agents; D000897:Anti-Ulcer Agents; D004338:Drug Combinations; D014663:Nasal Decongestants; D014311:Triprolidine; D054199:Pseudoephedrine; D002927:Cimetidine